# Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of INV-101 in Healthy Male and Female Subjects

> **NCT04531150** · PHASE1 · COMPLETED · sponsor: **Inversago Pharma Inc.** · enrollment: 40 (actual)

## Conditions studied

- Pharmacokinetic

## Interventions

- **DRUG:** INV-101
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04531150
- **Lead sponsor:** Inversago Pharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-08
- **Primary completion:** 2021-01-16
- **Final completion:** 2021-05-16
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04531150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04531150, "Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of INV-101 in Healthy Male and Female Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04531150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*